mRNA-3705

Phase 1RNA therapy

Moderna

mRNA-3705 is one of 41 biologic programs targeting Acute Kidney Injury. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Acute Kidney InjuryPhase 1

Active, not recruiting

Competition

Competitive Landscape

178 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

2 2

Truphylline

TThe Searle Company Limited Pakistan

Phase 3

2 3

Crestor

AstraZeneca

Preclinical

3 4

L-Alanyl/l-Glutamine

TTemple Therapeutics BV

Phase 3

1 5

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 6

Celexa

AbbVie

Preclinical

1 7

Proamatine

Takeda

Preclinical

1 8

Lexapro

AbbVie

Preclinical

1 9

Lescol

Novartis

Preclinical

1 10

Golytely

Bayer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1/2Active, not recruiting

Methylmalonic Acidemia

NCT04899310

Q2 2034

Phase 1/2Recruiting

ART

NCT05295433

Clinical

Trials by Indication[1]

Methylmalonic Acidemia1 trial

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Active, not recruiting· Moderna logo

Moderna·Phase 1/2·NCT04899310·74 enrolled

ART1 trial

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Recruiting· Moderna logo

Moderna·Phase 1/2·NCT05295433·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mRNA-3705. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-3705 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-3705. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: Moderna

mRNA-3705

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2034

Trials by Indication[1]

Methylmalonic Acidemia1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News